|
1
|
Chen LY, Hu A and Chang CJ: The
degradation mechanism of toxic atractyloside in herbal medicines by
decoction. Molecules. 18:2018–2028. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu J, Liu C, Shi K, Sun X, Song C, Xu K
and Liu Y: Atractyloside-A ameliorates spleen deficiency diarrhea
by interfering with TLR4/MyD88/NF-κB signaling activation and
regulating intestinal flora homeostasis. Int Immunopharmacol.
107:1086792022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang P, Cheng X, Sun H, Li Y, Mei W and
Zeng C: Atractyloside protect mice against liver steatosis by
sctivation of autophagy via ANT-AMPK-mTORC1 Signaling Pathway.
Front Pharmacol. 12:7366552021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li H, Shi X, Jiang H, Kang J, Yu M, Li Q,
Yu K, Chen Z, Pan H and Chen W: CMap analysis identifies
Atractyloside as a potential drug candidate for type 2 diabetes
based on integration of metabolomics and transcriptomics. J Cell
Mol Med. 24:7417–7426. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cho J, Zhang Y, Park SY, Joseph AM, Han C,
Park HJ, Kalavalapalli S, Chun SK, Morgan D, Kim JS, et al:
Mitochondrial ATP transporter depletion protects mice against liver
steatosis and insulin resistance. Nat Commun. 8:144772017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ling X, Zhou Y, Li SW, Yan B and Wen L:
Modulation of mitochondrial permeability transition pore affects
multidrug resistance in human hepatocellular carcinoma cells. Int J
Biol Sci. 6:773–783. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu WJ, Du Y, Wen R, Yang M and Xu J: Drug
resistance to targeted therapeutic strategies in non-small cell
lung cancer. Pharmacol Ther. 206:1074382020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aran V and Omerovic J: Current approaches
in NSCLC targeting K-RAS and EGFR. Int J Mol Sci. 20:57012019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu X, Yu L, Zhang Z, Ren X, Smaill JB and
Ding K: Targeting EGFRL858R/T790M and
EGFRL858R/T790M/C797S resistance mutations in NSCLC:
Current developments in medicinal chemistry. Med Res Rev.
38:1550–1581. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Song Y, Li C, Ren J, Fang M, Fang
J and Wang X: Brother of regulator of imprinted sites inhibits
cisplatin-induced DNA damage in non-small cell lung cancer. Oncol
Lett. 20:2512020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang
JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, et al: Gefitinib plus
chemotherapy versus chemotherapy in epidermal growth factor
receptor mutation-positive non-small-cell lung cancer resistant to
first-line gefitinib (IMPRESS): Overall survival and biomarker
analyses. J Clin Oncol. 35:4027–4034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soltanian S and Dehghani H: BORIS: A key
regulator of cancer stemness. Cancer Cell Int. 18:1542018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loukinov D: Targeting CTCFL/BORIS for the
immunotherapy of cancer. Cancer Immunol Immunother. 67:1955–1965.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Asano T, Hirohashi Y, Torigoe T, Mariya T,
Horibe R, Kuroda T, Tabuchi Y, Saijo H, Yasuda K, Mizuuchi M, et
al: Brother of the regulator of the imprinted site (BORIS) variant
subfamily 6 is involved in cervical cancer stemness and can be a
target of immunotherapy. Oncotarget. 7:11223–11237. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Fang M, Song Y, Ren J, Fang J and
Wang X: Brother of regulator of imprinted sites (BORIS) suppresses
apoptosis in colorectal cancer. Sci Rep. 7:407862017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Debruyne DN, Dries R, Sengupta S, Seruggia
D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, et al:
BORIS promotes chromatin regulatory interactions in
treatment-resistant cancer cells. Nature. 572:676–680. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang S, Reitze NJ, Ewing AL, McCreary S,
Uihlein AH, Brower SL, Wang D, Wang T, Gabrin MJ, Keating KE, et
al: Analytical Performance of a 15-Gene Prognostic Assay for
Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized
Tissue. J Mol Diagn. 17:438–445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu CQ, Ding K, Strumpf D, Weir BA,
Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et
al: Prognostic and predictive gene signature for adjuvant
chemotherapy in resected non-small-cell lung cancer. J Clin Oncol.
28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang M, Song Y, Ren J, Yuan H, Fang J, Yan
D, Zhang Y and Wang X: Atractyloside mimics BORIS knockdown
to induce DNA damage in colorectal cancer cells. Int J Clin Exp
Pathol. 11:3286–3293. 2018.PubMed/NCBI
|
|
24
|
Wang R, Wang S, Li Z, Luo Y, Zhao Y, Han
Q, Rong XZ, Guo YX and Liu Y: PLEKHH2 binds β-arrestin1 through its
FERM domain, activates FAK/PI3K/AKT phosphorylation, and promotes
the malignant phenotype of non-small cell lung cancer. Cell Death
Dis. 13:8582022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luoto KR, Meng AX, Wasylishen AR, Zhao H,
Coackley CL, Penn LZ and Bristow RG: Tumor cell kill by c-MYC
depletion: Role of MYC-regulated genes that control DNA
double-strand break repair. Cancer Res. 70:8748–8759. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arteaga CL: ErbB-targeted therapeutic
approaches in human cancer. Exp Cell Res. 284:122–130. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin X, Wang J, Shen H, Ran R, Xu K, Zhang
W, Tong X and Feng L: Curcumin co-treatment ameliorates resistance
to gefitinib in drug- resistant NCI-H1975 lung cancer cells. J
Tradit Chin Med. 37:355–360. 2017. View Article : Google Scholar : PubMed/NCBI
|
